Pancreas Screening in High Risk Individuals

Pancreas Screening in High Risk Individuals: A Prospective Cohort

Pancreas cancer is the 11th most common cancer in Canada but the 4th most common cause of cancer death because by the time pancreas cancer is detected, it is almost always too advanced for surgery. There are known factors that put individuals at higher risk for pancreas cancer. These include: certain genetic mutations, a family history of pancreas cancer, pancreas cysts and a new diagnosis of diabetes mellitus. Individuals with these risk factors are recommended to undergo pancreas screening with blood tests and yearly imaging tests of the pancreas. Our study will enroll patients with these risk factors and ensure they are managed as per guidelines. Prospectively collected data will include: patient clinicodemographic details, lifestyle factors, screening test results, clinical outcomes and patient reported outcome measures.

Study Overview

• Status: Not yet recruiting
• Conditions: Pancreas Cancer Screening

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Jennifer Telford, MD MPH; Phone Number: 254 1-604-688-6332; Email: jtelford@telus.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

High risk individuals referred for pancreas screening

Description

Inclusion Criteria:

• Family history of pancreatic cancer, pathogenic variant increasing risk of pancreatic cancer, IPMN, new onset diabetes.

Exclusion Criteria:

• Unable to give informed consnet

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
High risk individuals for pancreas cancer; Individuals undergoing pancreas screening

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of pancreatic cancer	10 years

Collaborators and Investigators

• Sponsor: University of British Columbia

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2025
• Primary Completion (Estimated): December 31, 2035
• Study Completion (Estimated): December 31, 2035

Study Registration Dates

• First Submitted: June 2, 2025
• First Submitted That Met QC Criteria: June 2, 2025
• First Posted (Actual): June 10, 2025

Study Record Updates

• Last Update Posted (Actual): June 10, 2025
• Last Update Submitted That Met QC Criteria: June 2, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Neoplasms by Site; Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: H25-01796

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No